Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 77123-60-5 | MDL No. : | MFCD09029299 |
Formula : | C8H6FN | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | HWMVCSBQJWRQNF-UHFFFAOYSA-N |
M.W : | 135.14 | Pubchem ID : | 12687362 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 38.74 |
TPSA : | 26.02 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.0 cm/s |
Log Po/w (iLOGP) : | 1.7 |
Log Po/w (XLOGP3) : | 1.59 |
Log Po/w (WLOGP) : | 1.9 |
Log Po/w (MLOGP) : | 2.48 |
Log Po/w (SILICOS-IT) : | 2.14 |
Consensus Log Po/w : | 1.96 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 2.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.12 |
Solubility : | 1.02 mg/ml ; 0.00752 mol/l |
Class : | Soluble |
Log S (Ali) : | -1.75 |
Solubility : | 2.42 mg/ml ; 0.0179 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -2.37 |
Solubility : | 0.579 mg/ml ; 0.00429 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 2.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.42 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P330-P363-P501 | UN#: | N/A |
Hazard Statements: | H302-H312-H332 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
88% | at 20℃; | Step 31d. 3-Ethynyl-4-fluorobenzenamine (Compound 0605); Compound 0604 obtained above was treated with 100 mg potassium hydroxide in 20 mL of methanol at room temperature overnight. The solution was concentrated, dilute with water, brought to neutrality, and then extracted with ether. The combined organic phase was dried over magnesium sulfate, concentrated to yield the title compound 0605 as a brown oil (1.49 g, 85percent): LCMS 136 [M+1]+. The product was used in the next step without further purification. |
85% | With potassium hydroxide In methanol at 20℃; | Compound 0604 obtained above was treated with 100 mg potassium hydroxide in 20 mL of methanol at room temperature overnight. The solution was concentrated, dilute with water, brought to neutrality, and then extracted with ether. The combined organic phase was dried over magnesium sulfate, concentrated to yield the title compound 0605 as a brown oil (1.49 g, 85percent): LCMS 136 [M+l]+. The product was used in the next step without further purification. |
85% | at 20℃; | Step 31d. 3-Ethynyl-4-fluorobenzenamine (Compound 0605) Compound 0604 obtained above was treated with 100 mg potassium hydroxide in 20 mL of methanol at room temperature overnight. The solution was concentrated, dilute with water, brought to neutrality, and then extracted with ether. The combined organic phase was dried over magnesium sulfate, concentrated to yield the title compound 0605 as a brown oil (1.49 g, 85percent): LCMS 136 [M+1]+. The product was used in the next step without further purification. |
225 mg | With potassium carbonate In methanol at 20℃; Inert atmosphere | 16 mg of potassium carbonate are added to a solution of 360 mg of 4-fluoro-3-[(trimethylsilyl)ethynyl]aniline in 5 ml of methanol. After stirring over night under argon and at a temperature in the region of 20° C., the medium is concentrated to dryness under reduced pressure, then taken up in 8 ml of water and neutralized with a few drops of hydrochloric acid (1 N), and then extracted three times with diethyl ether. The combined organic phases are dried over anhydrous magnesium sulphate, filtered and concentrated to dryness under reduced pressure. 225 mg of 3-ethynyl-4-fluoroaniline are obtained in the form of a brown oil |
[ 1173153-20-2 ]
2-((4-Fluorophenyl)ethynyl)aniline
Similarity: 0.80
[ 1161426-63-6 ]
4-Fluoro-3-methylbenzene-1,2-diamine hydrochloride
Similarity: 0.74
[ 1173153-20-2 ]
2-((4-Fluorophenyl)ethynyl)aniline
Similarity: 0.80
[ 1161426-63-6 ]
4-Fluoro-3-methylbenzene-1,2-diamine hydrochloride
Similarity: 0.74
[ 1173153-20-2 ]
2-((4-Fluorophenyl)ethynyl)aniline
Similarity: 0.80
[ 207226-02-6 ]
3-Ethynylaniline hydrochloride
Similarity: 0.69
[ 343866-99-9 ]
2-Ethynyl-1-fluoro-4-nitrobenzene
Similarity: 0.67
[ 1173153-20-2 ]
2-((4-Fluorophenyl)ethynyl)aniline
Similarity: 0.80
[ 1161426-63-6 ]
4-Fluoro-3-methylbenzene-1,2-diamine hydrochloride
Similarity: 0.74